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1. 1. Object of research
Homozygous and heterozygous disorders of genes encoding folate cycle enzymes: methy-
lenetetrahydrofolate reductase (MTHFR C677T) and methionine-synthase-reductase (MTRR A66G).
1. 2. Problem description
Modern development of molecular genetic technologies allows timely to diagnose hered-
itary diseases, which cause a significant part of reproductive losses (RL). And new global para-
digms of medicine (Predictive, Personalized, Preventive and Participatory, or 4P) help to build a 
multilevel preventive system of hereditary genetic pathology, which can positively affect the level 
of RL in the early stages of ontogenesis (pregametic, presygotic, embryonic and fetal) [1, 2]. For 
the solution of the whole task, the etiological factors and diagnostic markers for the destruction of 
human embryogenesis and development of the fetus (biochemical, molecular-genetic, cytogenetic, 
instrumental, etc.) permanently studied in all sides of the world.
Despite of the scientific researches’ successes over the past decades, a lot of RL remain with 
unexplained etiology. High rates of miscarriage and life-threatening birth defects depend on genet-
ic factors [3, 4]. This fact confirms the relevance and significance of our research.
1. 3. Suggested solution to the problem
Among all RL, genetic caused are most significant (16–55 %) [5]. Other important caus-
es are anatomical (5–29 %), infectious (2–45 %), endocrine (15–40 %), and immunological (up to 
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40 %). Another 20-40 % RLs remain unclear. The study of pathology of pregnancy and fetal de-
velopment associated with RL [6], led to a clear understanding of the causal relationship between 
disorders of the amino acids homocysteine and methionine in the blood, folic acid deficiency and 
polymorphism of genes encoding folate cycle (FC) enzymes [7, 8].
An in-depth study of the genes encoding the FC enzymes, namely methylenetetrahydrofo-
late reductase (MTHFR C677T) and methionine-synthase-reductase (MTRR A66G), was to study 
the relationship between homozygous and heterozygous types of inheritance, the strength and in-
fluence of their clinical manifestations of FC violations.
The aim of research includes study of the influence of social-medical and genetic risk fac-
tors on the level of reproductive losses, taking into account the strength of clinical manifestations 
of defective folate genes with different types of inheritance.
2. Materials and methods of research
In accordance with the purpose and objectives of our study, during 2011–2013, 154 patients 
of the diagnostic group (DG) with RL in anamnesis, and 160 patients of the control group (CG; 
without RL in anamnesis) were prospectively examined. All patients asked preconception care 
for planning future pregnancies into the Municipal non-Commercial Enterprise of Kharkiv Re-
gional Council “Inter-Regional Specialized Medical-Genetic Center – Center of Rare (Orphanic) 
Diseases” (MNCE KhRC “IRSMGC-CR(O)D”) for planning future pregnancies and conducting 
appropriate preconception care. DG patients were examined cytogenetically. According to the re-
sult, they were divided into 2 subgroups: DG1 (56 persons) – with a normal karyotype, and DG2 
(98 persons) – with a pathologically altered karyotype. Patient data is kept confidential. Patients 
were notified to participate in the study (written informed consent was obtained). The study was 
approved by the Bioethics Committee of Kharkiv National Medical University (protocol No. 6 dat-
ed October 03, 2011) as conducted in accordance with the WMA Declaration of Helsinki – Ethical 
Principles for Medical Research Involving Human Subjects, revised in Fortaleza, Brazil, Octo-
ber 2013).
The calculation of the correlation coefficient was performed according to the formula:














where x and y – variants of variation series comparing; dx and dy – deviation of each variant from 
its arithmetic mean.
The nature of the relationship between these parameters was determined using the rank 
correlation coefficient (r). Correlation was studied by the direction, strength, and form of the rela-
tionship. The strength of the connection was assessed on a scale:
– r=0.01–0.29 (weak connection); 
– r=0.3–0.69 (medium connection);
– r=0.7–0.99 (strong connection).
During the statistical processing of the obtained results the methods of calculation of rela-
tive and average values, estimation of their reliability, stratification and correlation-regression anal-
ysis were used. Maintenance of the study data bank, basic calculations of derivative indicators, fre-
quency response of characteristics were performed using Microsoft Excel 2016 software (license 
No. 00201-10554-16848-AA351), all calculations were performed using Statsoft Statistica 8.0 (license 
No. STA862D175437Q). In addition, the results of cytological examination of 6824 patients during 
the period 2008–2013 in the MNCE KhRC “IRSMGC-CR(O)D” were retrospectively studied.
3. Results
According to the results of a prospective study of 154 patients from DG, RL cases in an-
amnesis, which were represented by miscarriages, missed abortion, antenatal death, early neonatal 
death, ectopic pregnancies, multiple fetal birth defects, incompatible with life, were identified. The 
spectrum of these violations is shown in Table 1. The age of DG and CG patients ranged from 19 
to 47 years; the average age of DG patients was 29.9 years, CG – 28.6 years. CG patients asked for 
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routine examination and pregnancy planning into MNCE KhRC “IRSMGC-CR(O)D”, and did not 
have a burdensome obstetric anamnesis.
Table 1
RL varieties in patients from DG with a burdensome obstetric anamnesis (absolute value; %) 
RL in anamnesis Absolute val. %
One miscarriage 23 14.94
Two or more miscarriages 19 12.34
One ectopic pregnancy 8 5.19
Two ectopic pregnancies 1 0.65
Missed abortion 41 26.62
Antenatal fetal death 8 5.19
Early neonatal death 3 1.95
Multiple fetal birth defects, incompatible with life 1 0.65
Secondary infertility 7 4.55
Various RL combinations 43 27.92
Total 154 100.00
According to the study, most of DG patients had cases of one miscarriage (14.94 %), less 
often – two or more miscarriage (12.34 %). More than one from four women (26.62 %) had missed 
abortion, antenatal fetal death – 5.19 %, ectopic pregnancy – 5.19 %, two ectopic pregnancies – 
0.65 %, secondary infertility – 4.55 %, early neonatal fetal death – 1.95 %, multiple fetal birth 
defects, incompatible with life – 0.65 %. Combinations of different RL nosology were noted in 
every third (27.92 %) patient with DG, which proves the validity of an in-depth study of genetically 
determined RL etiology as a systemic phenomenon.
When comparing the results of cytogenetic examination of women of subgroups DG1 (with 
normal karyotype) and DG2 (with pathologically altered karyotype) with genealogical data of pa-
tients of all groups, special attention to the presence of reproductive disorders in blood relatives 
of patients, cardiovascular and oncology diseases was paid. It was established whether any of the 
relatives of the patients were registered with geneticists or other physicians. The structure of the 
revealed pathology in the pedigree of the examined patients is shown by Fig. 1.
The identified cases of all nosological forms predominated in DG patients. Thus, in the 
pedigrees of DG1 patients chromosomal pathology was recorded in 5.4 % cases (every eighteenth 
patient), DG2 – in 13.3 % cases (every seventh patient), and among patients CG was not detected. 
Among the identified cases of chromosomal pathology were two cases of Down syndrome, one 
of Klinefelter’s syndrome. All cases of fetal polyploidy were detected using invasive methods of 
prenatal diagnosis. Three cases of missed abortion in DG1 patients were identified as a result of 
chorionic biopsy. Gene pathology among relatives of patients of all groups was less compared to 
chromosomal: in CG – 3.1 %; DG1 – 7.1 %; DG2 – 8.2 %. Multifactorial pathology in pedigrees 
was observed most often: in CG – 81.3 %; DG1 – 91.1 %; DG2 – 99 % (Fig. 1).
Let’s analyze the burden of pedigrees of patients of all groups with somatic, psychoneuro-
logical and oncological diseases. The identified cases of somatic pathology belonged to diseases 
of the urinary, gastrointestinal, endocrine, cardiovascular and respiratory systems. The results of 
comparing the incidence rate are shown in Fig. 2 and in Table 2. A high proportion of cardiovas-
cular, oncological and psychoneurological pathology in the pedigrees of patients of all groups was 
found. Pathology of the cardiovascular system was recorded in CG – 34.38 %, DG1 – 46.43 %, 
DG2 – 97.96 %; oncological diseases in CG – 31.25 %, DG1 – 42.86 %, DG2 – 79.59 %; psychoneu-
rological diseases in CG – 21.88 %, DG1 – 37.5 %, DG2 – 44.9 %; diseases of the gastrointestinal 
tract in CG – 21.88 %, DG1 – 23.21 %, DG2 – 27.55 %; endocrine diseases in CG – 18.75 %, DG1 – 
17.86 %, DG2 – 22.45 %; respiratory diseases in CG – 12.5 %, DG1 – 16.07 %, DG2 – 7.14 %; dis-
eases of the urinary system in CG – 12.5 %, DG1 – 8.93 %, DG2 – 11.22 %. All types of pathology 
were more common in relatives of DG2 patients compared to DG1: cardiovascular system – by 
51.53 %; oncological – by 36.73 %; psychoneurological – by 7.40 %; endocrine – by 4.59 %; gastro-
intestinal tract – by 4.34 % and urinary system – by 2.29 %.
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CG – control 
group 
DG1 – diagnostic group 
(normal karyotype)
DG2 – diagnostic group 
(pathologically altered karyotype) 
Fig. 1. The burden of pedigree examined patients with DG and CG
CG – control 
group 
DG1 – diagnostic group 
(normal karyotype) 
DG2 – diagnostic group 
(pathologically altered karyotype) 
Fig. 2. Structural characteristics of multifactorial pathology in the pedigrees of the examined patients
The data in Table 2 show that the relatives of DG2 patients were most common: varicose veins 
(26.53 %), myocardial infarction (21.43 %), strokes (16.33 %), gastric and lung cancer (12.24 % each), 
mammary cancer (10.2 %), alcohol dependence and diabetes mellitus (12.24 % each), pancreatitis 
(8.16 %). The predominance of cardiovascular, oncological and psychoneurological pathology in the 
pedigree of patients in this group corresponds to the predominance of organ’s systems lesions in fe-
tus and newborns with birth defects. This proves the connection with the carrier and inheritance of 
mutant (polymorphic) alleles of the genes of the FC system, which are responsible for such malforma-
tions. The world scientific community has studied in detail the dependence of the functionality of FC 
genes in cases of MTHFR and MTRR gene polymorphism on the type of their inheritance (homozy-
gous and heterozygous), according to which the homozygous type of gene polymorphism inheritance 
reduces its functionality by approximately 70 % and heterozygous 35 % [9, 10].
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Table 2
Frequency and structural characteristics of pathology in the pedigrees of the surveyed families of diagnostic 
and control groups (absolute amount; %)
System, pathology
DG1 (n=56) DG2 (n=98) CG (n=32)
abs. % abs. % abs. %
pathology of the cardiovascular system
Hereditary thrombophilia 2 3.57 8 8.16 – –
Myocardial infarction 3 5.36 21 21.43 2 6.25
Ischemic heart disease, stenocardia 7 12.50 17 17.35 3 9.38
Varicose veins 4 7.14 26 26.53 2 6.25
Hypertension 8 14.29 16 16.33 3 9.38
Congenital heart disease 1 1.79 4 4.08 – –
Atherosclerosis 1 1.79 3 3.06 1 3.13
Total 26 46.43 96 97.96 11 34.38
oncological pathology
Gastric cancer 4 7.14 12 12.24 2 6.25
Bowel cancer 2 3.57 6 6.12 – –
Lung cancer 2 3.57 12 12.24 2 6.25
Laryngeal cancer 2 3.57 3 3.06 – –
Mammary cancer 4 7.14 10 10.20 1 3.13
Bladder Cancer 1 1.79 2 2.04 – –
Skin cancer – – 2 2.04 – –
Prostate adenoma – – 5 5.10 1 3.13
Benign uterine tumor 3 5.36 12 12.24 2 6.25
Benign ovarian tumor 6 10.71 14 14.29 2 6.25
Total 24 42.86 78 79.59 10 31.25
psychoneurological pathology
Stroke 6 10.71 16 16.33 4 12.50
Schizophrenia 2 3.57 5 5.10 1 3.13
Alcoholism 5 8.93 12 12.24 1 3.13
Epilepsy 4 7.14 6 6.12 – –
Migraine 1 1.79 2 2.04 1 3.13
Developmental delay 3 5.36 3 3.06 – –
Total 21 37.50 44 44.90 7 21.88
endocrine pathology
Diabetes mellitus 5 8.93 12 12.24 3 9.38
Obesity 2 3.57 6 6.12 2 6.25
Autoimmune thyroiditis 3 5.36 4 4.08 1 3.13
Total 10 17.86 22 22.45 6 18.75
pathology of the gastrointestinal tract
Gastroduodenitis 3 5.36 5 5.10 2 6.25
Peptic ulcer 4 7.14 7 7.14 2 6.25
Pancreatitis 2 3.57 8 8.16 – –
Gallstone disease 3 5.36 5 5.10 3 9.38
Liver Cirrhosis 1 1.79 2 2.04 – –
Total 13 23.21 27 27.55 7 21.88
respiratory pathology
Chronic bronchitis 4 7.14 3 3.06 2 6.25
Bronchial asthma 3 5.36 2 2.04 1 3.13
Chronic sinusitis 2 3.57 2 2.04 1 3.13
Total 9 16.07 7 7.14 4 12.50
pathology of the urinary system
Urolithiasis 3 5.36 4 4.08 2 6.25
Chronic pyelonephritis 2 3.57 7 7.14 2 6.25
Total 5 8.93 11 11.22 4 12.50
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In a retrospective study of the relationship between polymorphism of genes encoding the 
enzymes FC (C677T MTHFR and A66G MTRR), malformations and miscarriages diagnosed in 
6824 clinical cases for the period 2008–2013. A linear logistic regression calculation for dif-
ferent configurations of homozygous and heterozygous gene disorders in these patients were 
performed (Table 3). Comparisons were made with patients without polymorphisms of these 
genes. The group of patients with heterozygous type of MTHFR and MTRR genes polymorphism 
(named MTHFR1 and MTRR1) had “milder” consequences of this disorder (less reduction in 
genes functionality). The group of patients with homozygous type of MTHFR and MTRR genes 
polymorphism (named MTHFR2 and MTRR2), accordingly, had “more severe” consequences 
(greater reduction in genes functionality). This result of the study, which was partially discussed 
in [11], corresponds to the data of other researchers [12, 13]. The groups MTHFR1 and MTHFR2, 
MTRR1 and MTRR2 were compared with the groups of patients who did not record polymor-
phisms of the MTHFR and MTRR genes (named MTHFR0 and MTRR0). RL in anamnesis of pa-
tients MTHFR0 and MTRR0 were associated with other risk factors: primarily smoking, alcohol 
and drug use, psycho-emotional overload, the negative effects of harmful environmental and/or 
industrial factors, etc.
Table 3
Association of clinically manifested FC disorders with established polymorphic genes MTHFR and MTRR of 
hetero- and homozygous types of inheritance in patients with anamnestic confirmed RL, examined for the 
period 2008–2013 in MNCE KhRC “IRSMGC-CR(O)D”
Indicators Non-standardized coefficients Standardized coefficients t р 95.0 % TІB m Beta lower upper
Constanta 0.035 0.004 – 8.522 0.000 0.027 0.043
MTHFR1 0.999 0.004 0.359 280.396 0.000 0.992 1.006
MTHFR2 2.675 0.006 0.578 452.214 0.000 2.663 2.686
MTRR1 0.998 0.004 0.361 224.232 0.000 0.989 1.006
MTRR2 2.902 0.005 0.996 619.270 0.000 2.893 2.911
Note: t – t-statistics, p – statistical significance of the difference
The study (Table 3) showed that compared with the group of patients without confirmed 
polymorphism of MTHFR gene (MTHFR0) in subjects with heterozygous inheritance (MTHFR1) 
probably (p=0.00) and significantly increased the chances of RL (by 0.999 units, or 29.5 times); 
and at homozygous significantly (p=0.000; by 2,675 units, or 77.43 times). Similarly, compared 
with the group of patients without confirmed polymorphism of the MTRR gene (MTRR0) signifi-
cantly (p=0.000) increased the chances: in heterozygous inheritance (MTRR1) by 0.998 units, or 
29.51 times; when homozygous by 2,902 units, or 83.91 times.
Our data on the probable relationships of polymorphism of genes encoding FC (C677T 
MTHFR and A66G MTRR) and responsible for most fetal malformations and RL in general, 
were fully confirmed by correlation-regression analysis. Groups of homo- and heterozygous 
polymorphisms of the C677T MTHFR and A66G MTRR genes (MTHFR1; MTHFR2; MTRR1 and 
MTRR2) were studied in this investigation. Hypothesis about correlation between the degree of 
polymorphism C677T MTHFR and A66G MTRR genes with the “severity” of FC excitation in 
the range from “mild” (heterozygous polymorphism of one of the two genes) to quite “severe” 
(homozygous polymorphism for both genes) was proven and confirmed in variable series: – 
polymorphism of heterozygous type isolated by one gene; – polymorphism of heterozygous type 
by two genes; – polymorphism of homozygous type isolated by one gene; – polymorphism of ho-
mozygous type for one gene and the second heterozygous type; – polymorphism of homozygous 
type by two genes (Table 4).
The degree of gene polymorphism probably correlated by moderate force with the presence 
of MTHFR gene polymorphism (r=0.542; p=0.000) and by high force with MTRR gene polymor-
phism (r=0.798; p=0.000). In this case, it was determined that the degree of polymorphism has 
a probable weak relationship with heterozygous polymorphism of the genes MTHFR (r=0.222; 
p=0.000) and MTRR (r=–0.259; p=0.000), which provoke “milder” disorders of FC and, respective-
ly, responsible for smaller RL. In contrast, homozygous gene polymorphism is likely and strong-
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ly associated with “severe” FC disorders, which are responsible for greater RL risks: MTHFR 
(r=0.432; p=0.000) and MTRR (r=0.747; p=0.000).
Table 4
Correlation of clinically manifested FC disorders with polymorphic genes MTHFR and MTRR of hetero- and 
homozygous inheritance types of and with the degree of their polymorphism in patients with anamnestic 
confirmed RL (examined in 2008–2013 in MNCE KhRC “IRSMGC-CR(O)D”)
Genes MTHFR MTRR Degree of polymorphism MTHFR1 MTHFR2 MTRR1 MTRR2
MTHFR
r 1.000 –0.011 0.542** 0.624** 0.572** 0.012 –0.014
p – 0.370 0.000 0.000 0.000 0.305 0.233
n 6824 6824 6824 6824 6824 6824 6824
MTRR
r –0.011 1.000 0.798** –0.001 –0.013 –0.212** 0.882**
p 0.370 – 0.000 0.950 0.301 0.000 0.000




r 0.542** 0.798** 1.000 0.222** 0.432** –0.259** 0.747**
p 0.000 0.000 – 0.000 0.000 0.000 0.000
n 6824 6824 6824 6824 6824 6824 6824
MTHFR1
r 0.624** –0.001 0.222** 1.000 –0.284** 0.016 –0.008
p 0.000 0.950 0.000 – 0.000 0.192 0.498
n 6824 6824 6824 6824 6824 6824 6824
MTHFR2
r 0.572** –0.013 0.432** –0.284** 1.000 –0.001 –0.009
p 0.000 0.301 0.000 0.000 – 0.912 0.451
n 6824 6824 6824 6824 6824 6824 6824
MTRR1
r 0.012 –0.212** –0.259** 0.016 –0.001 1.000 –0.647**
p 0.305 0.000 0.000 0.192 0.912 – 0.000
n 6824 6824 6824 6824 6824 6824 6824
MTRR2
r –0.014 0.882** 0.747** –0.008 –0.009 –0.647** 1.000
p 0.233 0.000 0.000 0.498 0.451 0.000 –
n 6824 6824 6824 6824 6824 6824 6824
Note: r – correlation coefficient; p – statistical significance of the difference; n – total number of observations; ** – re-
liable relationship
4. Discussion
Our results on the greater dependence of the FC genes functionality of in cases of polymor-
phism MTHFR and MTRR genes by the type of their inheritance (homozygous and heterozygous) 
completely coincide with other studies. Thus, according to Greenberg J. A. et al. [11], the homozy-
gous type of inheritance of gene polymorphism reduces its functionality by 70 %, and heterozy-
gous – by approximately 35 %. Other studies have also shown a higher effect on the homozygous 
type of inheritance of these genes in FC disorders [12, 13].
However, there are no literary sources that would describe exactly how these observations 
affect the organization of medical care for patients with a burdened obstetric anamnesis. Determi-
nation of the type of inheritance of FC polymorphic genes makes it possible to collect statistics on 
the severity of clinical manifestations and build predictive models about the number of pregnancies 
with unfavorable outcomes, the number of disabled children of varying severity. A woman who 
has given birth to a child with a disability (birth defects) is virtually excluded from the number of 
women of reproductive age who will be planning another pregnancy. Naturally, the quality of life 
of the family in which the disabled child is growing will also be reduced. Our study also connects 
for the first time two such important aspects of genetically determined RL, such as the severity of 
the clinical manifestations of FC disorders and the possible necessary actions of medical services 
in preconception care for the next pregnancy.
The fact proved by us for the population of the Kharkiv region of Ukraine allows to 
plan budget expenditures for health care, taking into account the known annual number of 
miscarriages and congenital malformations of fetuses and newborns, as well as the estimated 
number of clinically manifested cases of FC disorders of varying severity. A woman in whom 
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a violation of the folate cycle could not be detected in the early stages of embryo and fetal de-
velopment, who has the most severe variant of the development of a congenital defect (homo-
zygous polymorphism, MTHFR2 and MTRR2), should be able to terminate the pregnancy both 
before 15 weeks of pregnancy, as and the right to a late abortion. Understanding the risk of the 
most severe clinical manifestations for the entire population of such patients allows discussing 
legislative changes on abortion issues.
All medical specialists (family doctors, pediatricians, obstetricians-gynecologists, pediatric 
surgeons) should be notified of the possibility of diagnosing the severity of clinical manifestations 
of folate cycle disorders. Their actions for early diagnosis and the necessary medication and dietary 
intervention can lead to a significant reduction in reproductive losses in both the Kharkov region 
and Ukraine.
Study limitations. Significant financial costs due to the high cost of genetic testing.
Prospects for further research. Further research is planned to determine the medical 
and social possibilities of optimizing the model of prevention of genetically determined repro-
ductive losses.
5. Conclusions
1. When studying the influence of medical-genetic risk factors to the level of anamnes-
tic confirmed in-depth studied causes of genetically determined RL as a systemic phenomenon 
was validate. Structural characteristics of RL were stated, most of which are combinations of 
different manifestations, or conditions and diseases such as: missed abortions, miscarriages, 
antenatal fetal death, ectopic pregnancies, secondary infertility, early neonatal fetal death and 
multiple intrauterine fetal malformations (birth defects). Genetically determined RL are pri-
marily associated with miscarriage and congenital malformations of embryo, fetus and new-
born. The most significant genetic factor of miscarriage and birth defects is FC genes poly-
morphism, which can be determined both by direct genetic tests and indirectly by impaired 
blood coagulation system parameters and amino acid metabolism (primarily homocysteine).
2. The high influence of hereditary medical-genetic factors on the increased risks of 
RL for population has been clarified. A significant predominance of all types pathology (chro-
mosomal, gene and multifactorial) in the pedigrees of those examined with a burdensome RL 
obstetric anamnesis of (compared with control, patients without anamnestical burdens) was 
found. First of all, this manifested itself in the form of cardiovascular, oncological and psycho-
neurological pathology among relatives of patients with RL, and the frequency of occurrence 
depended on the karyotype. 
3. The risk of reproductive loss is reliably associated with the type of inheritance of 
MTHFR and MTRR polymorphic genes: the most “severe” homozygous type of polymorphism 
of both genes, the least severe – the heterozygous monogenic type. Diagnosis of gene polymor-
phism allows timely correction of the condition with the help of vitamin therapy and diet, to 
make an informed decision on maintaining or terminating pregnancy. Determining the possi-
ble severity of clinical manifestations makes it possible to more accurately determine the RL 
risks.
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